Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAC-321 in Platinum-Refractory NSCLC
NCT00063219Phase 2Completed
- Sponsor
- Pfizer
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of milataxel in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Objective Tumor Response Rate. Status: completed.
02
Drugs
milataxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00063219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063219.